Fluoroethylnormemantine, a derivative of Memantine, acts as an N-methyl-D-aspartate (NMDA) receptor antagonist and can function as a positron emission tomography (PET) tracer known as [18F]-fluoroethylnormemantine. This compound displays anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.

Fluoroethylnormemantine (0.1-10 mg/kg; a single i.p.) exhibits anti-amnesic effects on Aβ 25-35-induced learning impairments in mice[1]. Administered at 0.1-10 mg/kg i.p. once daily for 7 days, it mitigates Aβ 25-35-induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1]. A single injection of Fluoroethylnormemantine (1-20 mg/kg) reduces behavioral despair in the forced swim test and decreases fear behaviors in the cued fear conditioning and extinction training in rats[2]. In male Swiss CD-1 mice (7-9 weeks) injected with Aβ 25-35, dosages of 0.1-10 mg/kg administered i.p. 30 minutes before behavioral tests attenuated Aβ 25-35-induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit.